A Crypto-Transethosomal Gel for Topical Treatment of Melanoma

IN606751BActive Publication Date: 2026-10-23R PRABHU +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202541123309
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2025-12-07
Publication Date
2026-10-23
Estimated Expiration
2045-12-07

AI Technical Summary

Technical Problem

Conventional treatments for melanoma, including surgery, immunotherapy, and systemic chemotherapeutics, are associated with severe side effects, drug resistance, and poor selectivity, limiting their effectiveness due to systemic toxicity and poor drug delivery to the tumor site.

Method used

A novel crypto-transethosomal gel formulation combining cryptosomes and transethosomes, encapsulating mequinol and curcumin, provides enhanced drug stability, skin penetration, and targeted delivery, using a Carbopol-based gel system with PEG adsorption for improved encapsulation and stability, and stealth coating to evade immune recognition.

Benefits of technology

The formulation achieves sustained and targeted drug delivery to melanoma lesions, minimizing systemic exposure and side effects, with improved therapeutic efficacy through synergistic action of mequinol and curcumin, enhancing cytotoxicity and oxidative stress sensitivity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A Crypto-Transethosomal Gel for Topical Treatment of Melanoma A topical formulation comprising crypto-transethosomes is provided. The crypto-transethosomes include a soya lecithin, an edge activator, ethanol and Triethanolamine wherein a surface of the crypto-transethosome is modified with a polymer PEG 6000. The crypto-transethosomes may be incorporated into Carbopol 934 hydrogel compositions. The present formulations are useful for the delivery of Mequinol and Curcumin for topical melanoma treatment.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTIONThe present invention relates to cryptosome delivery systems for pharmaceuticalagents, and more particularly to crypto-transethosomes in a gel for topicalmelanoma treatment.BACKGROUND OF THE INVENTIONMelanoma is a highly aggressive form of skin cancer arising from uncontrolledproliferation and malignant transformation of melanocytes. It is characterized byexcessive melanin synthesis, rapid metastasis, and resistance to conventionalchemotherapy and radiotherapy. Early and localized intervention is crucial sincesystemic spread drastically reduces survival rates. Melanoma management hasadvanced significantly over the past decade, with considerable impact on theprognosis of the disease. Improved surveillance, widespread use of sentinel lymphnode (SLN) biopsy, and advances in systemic therapy have all contributedconsiderably to the decrease in melanoma mortality (Cancers (Basel), 2025; Sep5;17(17):2920). Melanoma represents one of the treatment-resistant forms of skincancer, necessitating the development of advanced topical delivery systems thatenable localized, sustained, and effective drug delivery while minimizing systemicexposure.Conventional treatments, including surgery, immunotherapy, and systemicchemotherapeutics, are often associated with severe side effects and poor patienttolerance. The development of drug resistance, poor selectivity, and systemictoxicity limit the success of current melanoma therapies. Targeted topical therapyprovides a promising alternative for localized melanoma, enabling high local drugconcentration at the tumour site with reduced systemic exposure.A rationally designed topical formulation can minimize side effects, enhance drugretention within the skin layers, and improve therapeutic efficiency in early-stageor superficial melanoma.Vesicular delivery has been a popular method of drug delivery in recent years. TheVesicular Drug Delivery Systems (VDDS) are colloidal dispersions whereamphiphilic molecules self-assemble into highly ordered, concentric bilayerstructures in water. VDDS has a number of advantages, but it also has several severedrawbacks that limit its use. Drugs were passively loaded, which can lead to drugleakage during preparation, preservation, and transit in vivo.The present inventors develop a novel drug delivery system ie.cryptotransethosomes in which they combine the benefits of both cryptosomes andtransethosomes and solve the shortcomings of cryptosomes and transethosomes likeinstability, leakage, fusion, and premature drug release.Transethosomes integrates features of both ethosomes and transferosomes vesicles.They have more excellent deformability and flexibility and allowing them torecover their form after penetrating cells. The feature of transethosomes improvetransdermal drug delivery and also offer significant benefits regarding patientcompliance, stability, and biocompatibility.The cryptosome known as stealth liposomes or immune-liposomes, composed ofliposomes and poloxamer molecules, which can encapsulate and deliver drugs,improving stability, bioavailability, and targeted administration.To combine the advantages of both vesicular system of cryptosome andtransethosomes, the present inventors developed crypted vesicular systems byincorporating a protective outer shell or crypt, often made of polymers, surfactants,or biocompatible lipids. This crypt acts as a secondary barrier, shielding the innervesicle from environmental degradation, immune recognition, rapid clearance andenzymatic attack, thereby prolonging its circulation time and improving therapeuticefficacy.The present invention strategically selects the active ingredients such as mequinoland curcumin as dual therapeutic agents owing to their synergistic mechanisms ofaction. Mequinol acts as a melanocytotoxic compound targeting abnormalmelanocytes, whereas Curcumin provides potent antioxidant activity and inhibitionof glutathione S-transferase (GST), enhancing the cytotoxic effect throughincreased oxidative stress sensitivity in melanoma cells.Mequinol (4-hydroxyanisole) acts as a depigmenting and cytotoxic agent byselectively targeting melanocytes, thereby acting as a melanocytotoxic agent. Itsselective action on pigment-producing cells makes it valuable in treatingmelanocytic lesions and early melanoma. However, Mequinol exhibits limitedaqueous solubility and low permeability across the skin barrier, resulting in limitedtopical bioavailability.Curcumin, a natural polyphenolic compound from Curcuma longa, shows potentantioxidant, anti-inflammatory, and anticancer properties. Curcumin is a potentGlutathione S Transferase Inhibitor, reducing the antioxidant defense of melanomacells and promoting oxidative stress-induced apoptosis. By inhibiting GST,Curcumin sensitizes tumor cells to therapeutic agents and enhances cytotoxicitythrough accumulation of reactive oxygen species. This property complementsMequinol's mechanism, contributing to effective melanoma suppression. It exertscytotoxic effects on melanoma cells by inducing apoptosis, suppressing NF-κBactivation, and inhibiting angiogenesis and tumor proliferation. The combination ofMequinol and Curcumin is scientifically justified because Mequinol destroysproliferated melanocytes while Curcumin inhibits Glutathione S Transferase inmelanoma cells. Together, these agents showed a synergistic effect, improvingtherapeutic outcome by dual inhibition of melanogenesis and tumor progression.SUMMARY OF THE INVENTIONThe first aspect of the invention is to formulate and evaluate Crypto-Transethosomal gel loaded with Mequinol and Curcumin for the topical treatmentof melanoma, emphasizing enhanced drug stability, skin penetration, and targeteddrug delivery.Another aspect of the invention is to develop vesicles by combining Cryptosome(lipid bilayer) and Transethosome (ethanol+ edge activator) technologies using theEthanol injection method.Yet another aspect of the invention is to encapsulate Mequinol (moderatelyhydrophilic) and Curcumin (hydrophobic) into the vesicles for effective drugdelivery to target site.Yet another aspect of the invention is to characterize the formulated Crypto-transethosome vesicles for particle size, Entrapment efficiency and Morphologicalevaluation.Yet another aspect of the invention is to incorporate the Crypto-transethosomevesicles into Carbopol based gel system.Yet another aspect of the invention is to optimize and examine the topical gelpreparation and evaluate the gel for physicochemical properties including pH,viscosity, spreadability and drug content.The aspect of the invention is to provide a Crypto-Transethosomes deliverycomposition with remarkably improved encapsulation efficiency and stability, ascompared with the known Crypto-Transethosome, and a preparation methodthereof.Further another aspect of the invention is to provide a novel Crypto-Transethosomein a Carbopol 934 hydrogel and encapsulated together with a drug by physical orchemical binding in order to further improve encapsulation efficiency and stability,a composition including the structure, and a preparation method thereof. Carbopol934 acts as a thickening, gelling, and bioadhesive polymer that ensures prolongedresidence time on the skin surface, enhancing localized drug absorption.Further another aspect of the invention is to develop a hybrid system to enhancedrug penetration, minimize systemic side effects, and improve therapeutic efficacyagainst superficial or early-stage melanoma lesions.In the present formulation, the present inventors develop Crypto-Transethosomesby PEG adsorption on transethosomes, combining the advantages of bothcryptosome and transethosome systems-ethanol-induced flexibility, edgeactivator-based deformability, and PEG-mediated stability.Yet another aspect of the invention is to develop vesicles which can encapsulateboth Mequinol and Curcumin, protecting them from oxidation, photodegradation,and hydrolysis while ensuring sustained release.Yet another aspect of the invention is to develop and incorporate the optimizedvesicular system into a Carbopol-based gel provides a stable and user-friendlyvehicle suitable for topical application.Yet another aspect of the invention is to develop the gel base provides smoothconsistency, pH compatibility, non-greasy feel, and good spreadability, ensuringbetter patient compliance.Yet another aspect of the invention is to develop the therapeutically effectiveCrypto-Transethosomal gel for the treatment of Melanoma.DETAILED DESCRIPTION OF THE INVENTIONThe Crypto-Transethosomes are combination of cryptosomes and transethosomescomposition which comprises of crypto coating agents, edge activator,phospholipids and ethanol embedded with one or more delivery agents. Thecommonly used crypto coating agents are Poloxamers and Polyethylene glycol(PEG). The poloxamer is also termed as pluronics are synthetic, non-ionic,Polyethylene Oxide (PEO), Polypropylene Oxide (PPO), PEO-triblocks co-polymers of varying molecular weights. The hydrophobic Polypropyleneoxidegroups at the centre is bonded with two hydrophilic polyethylene oxide groups. Thepolymers of hydrophilic PEO groups on each side of the PPO units can providesteric hindrance and thus protection to the bilayer surface. This nature makes themuseful as emulsifiers and stabilizers. Various lipids includes either phospholipidslike phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, phosphatidyl-ethanol amine, phosphatidylinositol, or the other lipids like sphingolipids,glycolipids, fatty acid, and cholesterol at various proportions were used for theformation of lipid bilayer.Cryptosomes are formed from liposomes and poloxamer / PEG molecules. Abovethe critical micellar temperature, the polaxamer molecules form micelles, and afraction of them get introduced into the surface of liposome thus preventing theiradhesion to the cells. Polaxamer molecules dissociate below their critical micellarneighbouring cells and influence the holding of liposome on the adjacent cells. Thetargeted release of agents involves the introduction of components into themonomers and cooling the target site, which confines the liposomes at or near thetargeted site. The liposomes are prepared by the various method. The lipid vesiclescan be prepared by standard techniques like sonication and extrusion. They can alsobe synthesised from reversed phase evaporation, detergent dialysis and freeze-thawing. After various steps involved in the synthesis of liposome, the polaxamermolecules are incorporated into it to form the Cryptosomes. The liposomescollected is treated with poloxamer molecules and get embedded in it. Thestealthing of liposome is primarily done by using polyethylene glycol andpoloxamer or polymer. This results in the formation of Cryptosomes. The PEG ofmolecular weight in the range of 1000 to 6000 exhibit prolonged circulation anddecreased uptake by mononuclear phagocytic system (MPS). The most commonlyused phospholipid in the formulation is phosphatidylcholine, it forms theelementary unit of plasma membrane, it acts as a safeguard of polyphenolics, and italso exhibit both hydrophilic and lipophilic analogs, the phosphatidyl moiety beinglipophilic and choline moiety being hydrophilic nature.They are sterically well stabilized and is used for targeted drug delivery. It exhibitsreduced recognition and uptake by macrophages and prolonged circulation andhalf-life. It is efficiently used in dose-independent pharmacokinetics. It exhibitsincreased uptake in vivo by solid tumors and breast cancer. Decreased tendency toleak the drug during blood circulation.The rigidity of the phospholipid bilayer and surface hydrophilicity, both of whichare essential to keep the vesicles in the circulation, explain why cryptosomes havesuch a long lifetime and also prevention of macromolecule adsorption on thesurface of such vesicles. Cryptosomes are liposomal compositions that include oneor more delivery agents and are built up of poloxamer molecules (polymers) andliposomes.Transethosomes are lipid-based vesicular drug carriers that include phospholipid,ethanol, edge activator, and water. Transethosomes deliver the drug inepidermis / dermis region. A hydrophilic head and a hydrophobic tail are present. Anedge activator is used to soften the bilayer. Ethanol promotes lipid perturbation. Themajor advantage of formulating transethosomes is that it penetrates deeper into theabnormal cancer cell layers and release the therapeutic agent in sustained manner.Phospholipids' principal function is to act as a carrier to deliver medication particlesstraight into the skin. A hydrophilic head and a hydrophobic tail are present in thelipid vesicular system. An edge activator that is used to soften the bilayer.Additionally, it can be used to enhance the vesicle's permeability properties.Ethanol provides adaptability and flexibility for the formulation of nano-vesicularsystems, which can easily permit them to perforate inside the stratum corneumthrough very small openings due to the process of fluidization.When the edge activator and ethanol are combined, it causes the transposition ofthe lipid bilayer, which can also cause a more deformable structure, which caneasily penetrate into the deeper skin layer.Suitable phospholipids include, but are not limited to, phosphatidyl choline (PC),phosphatidic acid (PA), phosphatidyl ethanolamine (PE), phosphatidyl glycerol(PG), phosphatidyl serine (PS), and phosphatidyl inositol (PI), dimyristoylPhosphatidyl choline (DMPC), distearoyl phosphatidyl choline (DSPC),dioleoylphosphatidyl choline (DOPC), dipalmitoyl phosphatidyl choline (DPPC),dimyristoyl phosphatidyl glycerol (DMPG), distearoyl phosphatidyl glycerol(DSPG), dioleoyl phosphatidyl glycerol (DOPG), Dipalmitoyl phosphatidylglycerol (DPPG), dimyristoyl phosphatidylserine (DMPS),distearoylphosphatidylserine (DSPS), dioleoylphosphatidylserine (DOPS),dipalmitoylphosphatidylserine (DPPS), dioleoylphosphatidylethanolamine(DOPE), palmitoyl oleoylphosphatidylcholine (POPC), palmitoyl oleate Oil-phosphatidylethanolamine (POPE), and dioleoyl-phosphatidylethanolamine 4- (N-maleimidomethyl) -cyclohexane-1-carboxylate (DOPE-mal),dipalmitoylphosphatidylethanolamine (DPPE), dimyristoyl phosphoethanolamine(DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16- -Monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidylethanolamine(SOPE), 1,2-dielideyl-sn-glycero-3-phospho There may be mentionedethanolamine (phophophenololamine) (trans-DOPE), and cardiolipin.Lipid extracts, such as egg PC, heart extract, brain extract, liver extract, and soy PCare also useful in the present invention. In some embodiments, soy PC can includeHydro Soy PC (HSPC). In certain embodiments, the lipids can include derivatizedlipids such as PEGylated lipids. Derivatized lipids can include, for example, DSPE-PEG2000, cholesterol-PEG2000, DSPE-polyglycerol, or other derivativescommonly known in the art.Phospholipids constituting the Crypto-transethosomes may be a naturalphospholipid and / or a synthetic lipid. The natural phospholipid may be at least oneselected from the group consisting of cholesterol, egg yolk lecithin(phosphatidylcholine), soybean lecithin, lysolecithin, sphingomyelin, phosphatidicacid, phosphatidylserine, phosphatidylglycerol, phosphatidylinositol,phosphatidylethanolamine, diphosphatidylglycerol, cardiolipin, and plasmalogen.A proportion of the phospholipids in all components of the Crypto-transethosomes is preferably less than 0.1 wt % to 10 wt %. More preferably, theproportion of the phospholipids in all components of the Crypto-transethosomes is1 wt % to 4 wt %. When the proportion of the phospholipids in all components ofthe Crypto-transethosomes is less than 0.1 wt %, it is difficult to encapsulate a druginside the Crypto-transethosomes. When the proportion of the phospholipids in allcomponents of the Crypto-transethosomes is 10 wt % or more, it is difficult todissolve the phospholipids in an aqueous solution, and dispersion is decreased, andtherefore, nanoparticles may not be obtained.The synthetic lipid may be at least one selected from the group consisting of dicetylphosphate, distearoylphosphatidylcholine, dioleoylphosphatidylethanolamine,dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylethanolamine,dipalmitoylphosphatidylserine, eleostearoylphosphatidylcholine,eleostearoylphosphatidylethanolamine, and eleostearoylphosphatidylserine. Aproportion of the synthetic lipid is preferably 0 wt % to 0.1 wt %. Although thesynthetic lipid is not necessarily included in the components of Crypto-transethosomes , it is preferably included in an amount of less than 0.1 wt % toimprove encapsulation efficiency. When the synthetic lipid is included in an amountof 0.1 wt % or more in the Crypto-transethosomes , vesicles are not stabilized andtend to rapidly release the internal drug.When cholesterol is added as a lipid component, it contributes to more stableformation of Crypto-transethosomes. Cholesterol is wedged between phospholipidsto make the membrane structure more rigid, and therefore, contributing to formationof a stable phospholipid membrane. Therefore, a proportion of cholesterol in allcomponents of the Crypto-transethosomes is preferably 0.01 wt % to 0.5 wt %. Theproportion of cholesterol in all components of the Crypto-transethosomes is morepreferably 0.1 wt % to 0.2 wt %. A proper amount of cholesterol stabilizes thephospholipid membrane to contribute to particle stability.Phospholipids that may be incorporated in the transethosome include, but are notlimited to, L-α-phosphatidylcholine, dilauroyl L-α-phosphatidylcholine,phosphatidylcholine stabilized with ascorbyl palmitate (i.e. Phospholipon 90 G),soy or egg phosphatidylcholine, dipalmitoylphosphatidylcholine,phosphatidylethanolamine (PE), phosphatidylserine (PS), pho sphatidic acid (PA),phosphatidylinositol (PI), phosphatidylglycerol (PG) and cardiolipin (CL).In some embodiments, the formulation includes a Mequinol and Curcumin tophospholipid molar ratio from 1:1 to 1:5, e.g. from 1:2 to 1:4. The at least onephospholipid is generally present in an amount ranging from about 0.1 to about5.0% (w / v) of the total formulation volume, such as from about 0.5 to about 4.0%w / v or about 1 to about 3.5% w / v.Ethanol which is the most important component of the Crypto-transethosomes plays a role in making the lipid membrane flexible to increase atransdermal absorption rate. A size of nanoparticles, encapsulation efficiency, lipidflexibility, etc. may be greatly changed according to the content of ethanol, andtherefore, the proportion of ethanol is very important. A proportion of ethanol in allcomponents of the Crypto-transethosomes is preferably 0.1 wt % to 20 wt %. Theproportion of ethanol in all components of the Crypto-transethosomes is morepreferably 2 wt % to 8 wt %.The presence of ethanol in the lipid layer of the crypto-transethosome provides asofter and malleable vesicle structure, which gives more freedom, elasticity andstability to its membrane. In some embodiments, the ethanol is present in ahydration medium, e.g. water or a buffer solution such as a phosphate buffersolution, in an amount of 5-60% v / v. e.g. 12-50% v / v.When the content of ethanol is too low, the transdermal absorption rate may not beincreased. When the content of ethanol is too high, skin irritation is increased and adrug is released therefrom. Thus, the Crypto-transethosomes becomes useless.Furthermore, the Crypto-transethosomes encapsulates active ingredients likeMequinol and Curcumin. The crypto-transethosomal gel releases mequinol andcurcumin through diffusion and vesicle-mediated delivery. As the gel hydrates,drug-loaded crypto-transethosomes diffuse outward. On reaching the skin, theirethanol and surfactant-rich bilayers enhance penetration by fluidizing stratumcorneum lipids, allowing vesicle fusion and gradual drug release into deeper layersfor sustained and targeted delivery.Crypted-transethosomes, on the other hand, are PEG-bonded vesicular systemsdeveloped for systemic and targeted drug delivery. In this formulation, PEG iscovalently bonded or chemically grafted onto the vesicle surface (usually throughPEGylation of phospholipids or surfactant molecules). Crypto-Transethosomescombines the benefits of both Cryptosomes and transethosomes, thus suitable fortopical and localized delivery. As a transethosome it can easily penetrate throughthe skin pores, and as a Cryptosomes, it can protect the vesicle and loaded drugfrom immune system.These are Ultra-deformable PEG adsorbed vesicles which can accommodate bothlipophilic and hydrophilic drugs. Due to stealth coating, it also provides addedstability to the vesicles and can facilitate targeted drug delivery.Stealth coating for ethosomes involves adding materials, often polymers like PEG(Polyethylene Glycol), to their surface to camouflage them from the immunesystem (reticuloendothelial system - RES), preventing rapid clearance from thebloodstream, thereby prolonging circulation time for better drug delivery, especiallyin systemic therapies, by reducing opsonization and phagocytosis, making them"invisible" to immune cells. While traditional transethosomes excel at skinpenetration due to high ethanol content, adding stealth coatings adapts themfor systemic applications, similar to PEGylated liposomes, allowing targeted drugdelivery to tumors or other sites.The gel-forming substance of the present invention can e.g., be selected from thegroup consisting of PEG 6000 and Poloxamers.Crypto-transethosomes are PEG-adsorbed vesicular systems designed primarily forlocalized or topical drug delivery. They are a modified form of transethosomes-flexible lipid vesicles composed of phospholipids, ethanol, and edge activators-onto which polyethylene glycol (PEG) molecules are physically adsorbed on thevesicle surface.This PEG adsorption forms a protective hydrophilic shield, improving the vesicle'sstability and hydration at the skin interface without significantly altering its surfacecharacteristics. In this regard, the hydrogel may be prepared by using a naturalsubstance and / oral synthetic substance. For example, the hydrogel may be at leastone selected from the group consisting of a carbomer, agar, a collagen peptide,hyaluronic acid, starch, modified starches such as hydrolyzed starch and cross-linked starch, dextrin, gamma PGA, carrageenan, gums such as gum Arabic andxanthan gum, carboxymethyl cellulose (CMC), gelatin, pectin, alginic acid, andchitosan.The gel-forming substance of the present invention can e.g., be selected from thegroup consisting of agar, alginates, alginic acids, Arabic gum, gelatine, starch,tragacanth gum, methylcelluloses, hydroxyethylcelluloses,carboxymethylcelluloses, polyacrylic acids and / or combinations thereof. Inpreferred embodiments, acrylic acid polymers are applied. Polymers complying theUSP Carbomer 940 monograph like Carbopol 908NF or carbopol 934 or Carbomer940) are preferred from this group. The gel-forming substances may comprisepolyacrylates, polymethacrylates, polyacrylic acids, polymethacrylic acids,polyvinylalcohols and combinations thereof. Polyacrylic acids are particularlypreferred. In preferred embodiments of the invention, gel-forming substances areused in the form of hydrogels. A hydrogel, as used in the present invention, is a gelon the basis of a hydrophilic composition or compound, which is capable ofabsorbing and / or releasing a certain amount of liquid, in particular water. The pHmay be in the range from 3 to 7, more preferably from 4 to 6.5 and even morepreferably in the range from 5 to 6.The gel-forming substance is present in the preparation according to the inventionat between about 0.1% and about 10%, preferably between about 0.5% and about5%, more preferably between about 1.0% and about 5%, and most preferably 3.5%.All these percentages are wt.-%, based on total preparation weight.The composition may include a hydrophilic non-ionic surfactant in an amount offrom about 1% to about 20% by weight of the composition, optionally from about2% to about 15% by weight of the composition. Preferably, the compositionincludes a hydrophilic non-ionic surfactant in an amount of from about 2% to about10% by weight of the composition, such as from about 2.5% to about 5% by weightof the composition.The hydrophilic non-ionic surfactant may be a polyethylene glycol ester of avegetable oil containing at least 20 moles of ethylene oxide groups / mole ofglyceride. Suitable polyethylene glycol esters are typically selected frompolyoxyethylene castor oil derivatives (e.g., PEG 20, 30, 35, 38, 40, 50 and 60castor oil or PEG 20, 25, 30, 40, 45, 50, 60 and 80 hydrogenated castor oil), PEG20 and 60 corn glycerides, PEG 20 and 60 almond glycerides, PEG 40 palm kerneloil, sodium laurate sulfate, sucrose esters (e.g., sucrose stearate, sucrose distearate,sucrose cocoate or sucrose monolaurate), PEG cocoglyceride, PEG 8caprylocaprate, polyglyceryl esters and linolenamide DEA. In a preferredembodiment, the hydrophilic non-ionic surfactant is sucrose distearate, such as thatavailable under the trade name Sisterna SP30.In certain embodiments, the hydrophilic non-ionic surfactant may be a mixture ofacrylamide acryloyldimethyl taurate copolymer, isohexadecane and polysorbate 80,such as that available under the trade name SEPINEO P600. The hydrophilicnon-ionic surfactant may be an alkylpolyglucoside, such as that available under thetrade name SEPINEO SE68.A lipophilic non-ionic surfactant may be present in an amount of from about 0.1%to about 5% by weight of the composition. Surfactants are generally irritants, andso it is preferred to use only low levels of certain surfactants. However, somelipophilic non-ionic surfactants, such as monoglyceride esters, are less irritative andso can be present in higher amounts without causing significant levels of skinirritation.The lipophilic non-ionic surfactant may be selected from monoglyceride esters ofC6 -C22 fatty acids (e.g., glyceryl monocaprylate, glyceryl monocaprate, glycerylmonostearate, glyceryl monobehenate), diglyceride esters of C6 -C22 fatty acids(e.g., glyceryl dilaurate), mono- and diglyceride esters of C6 -C22 fatty acids (e.g.,caprylic / capric mono- and diglyceride, glyceryl mono- and diricinoleate),propylene glycol esters of C6 -C22 fatty esters (e.g., propylene glycolmonocaprylate, propylene glycol monolaurate), dialkylene glycol monoalkyl ethers(e.g., diethylene glycol monoethyl ether), polyglyceryl C6 -C22 fatty acid esters(e.g., polyglyceryl-3-diisostearate), polyethylene glycol esters of atriglyceride / vegetable oil containing 4 to 8 moles of ethylene oxide groups / mole ofglyceride (e.g., PEG-6 corn oil, PEG-6 almond oil, PEG-6 apricot kernel oil, PEG-6 olive oil, PEG-6 peanut oil, PEG-6 palm kernel oil, hydrogenated palm kernel oil,PEG-6 triolein, PEG-8 corn oil), polysorbates (e.g., polysorbate 20, polysorbate 40,polysorbate 60, polysorbate 80). In a preferred embodiment, the lipophilic non-ionic surfactant is a sorbitan ester, such as that available under the trade nameSpan 120. In a preferred embodiment, the lipophilic non-ionic surfactant is anoleoyl macrogol-6 glyceride, such as that available under the trade name LabrafilM1944 or a lauroyl polyoxyl-6 glyceride, such as that available under the tradename Labrafil M2130.The aqueous composition component may include an aqueous buffer solution. Theuse of buffer solutions means that fluctuations in pH can be minimized and thus thepH can be kept more readily within the desired pH range, such as at a pH of betweenpH 4.5 and pH 8.2.The composition may include one or more emulsifiers selected from e.g.,polyacrylates, polycarbophils, poloxamers, hyaluronic acid, xanthan, naturalpolysaccharides, chitosan and cellulose-derivatives. Suitable cellulose-derivativeviscosity enhancers include hydroxyalkyl cellulose polymers (e.g., hydroxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose (hypromellose) andhydroxypropylmethyl cellulose), carboxymethyl cellulose, methylhydroxyethylcellulose and methylcellulose, carbomer (e.g., Carbopol), and carrageenans. Incertain preferred embodiments, the emulsifier is hydroxyethyl cellulose, such asthat available under the trade name Natrosol (e.g., Natrosol 250 HX, NatrosolPLUS CS, Grade 300 etc.) and Methocel. In certain preferred embodiments, theemulsifier is hydroxypropyl cellulose, such as that available under the trade nameKlucel and Methocel. Typically, the emulsifier is present in an amount of fromabout 1% to about 20% by weight of the composition, such as about 1%, 3%, 5%,10%, 15% or 20% by weight of the composition. The composition may includemore than one viscosity enhancers, such as two or three viscosity enhancers.It may be useful to include one or more penetration enhancers. Typical penetrationenhancers include propylene carbonate, transcutol, pyrrolidones such as N-methylpyrrolidone or N-hydroxyalkylpyrrolidone, azone, menthol, eucalyptol,nicotinamide, glycerol, mono-di- or polyglycols, ethylacetate or Eugenol. Aparticularly preferred penetration enhancer is α-tocopherol. A penetration enhancermay be present in an amount of from about 0.01% to about 20% by weight of thecomposition, such as from about 0.1% to about 15%, e.g., about 0.1%, about 0.5%,about 1%, about 1.5%, about 2%, about 2.5%, about 3%, or about 5% by weight ofthe composition.The phospholipids used to prepare the Crypto-transethosomes compositionsdescribed herein may comprise a transition phase temperature of about 10°C. toabout 25°C. In some instances, the phospholipids comprise a transition phasetemperature of about 10°C., 12°C., 14°C., 16°C., 18°C., 20°C., 22°C., 24°C.,26°C., 28°C., 30°C., 32°C., 34°C., 36°C., 38°C., 40°C., or more than 40°C.In some instances, the phospholipids comprise a transition phase temperature in arange of about 10°C. to about 40°C., about 12°C. to about 36°C., about 14°C. toabout 32°C., about 16°C. to about 20°C., or about 21°C. to about 25°C.Methods for generation of Crypto-transethosomes compositions as described hereinmay result in an entrapment efficacy of not more than 100%. In some instances, theentrapment efficacy is no more than 50%, 60%, 70%, 80%, 90%, 95%, 99%, or99.5%.Described herein are Crypto-transethosomes compositions, wherein the activeagent comprises a percentage of the composition. In some embodiments, the activeagent is provided at least or about 0.0001%, 0.0005%, 0.00055%, 0.001%, 0.005%,0.01%, 0.02%, 0.05%, 0.10%, 0.20%, 0.25%, 0.50%, 0.75%, 1.0%, 1.5%, 2.0%,2.5%, 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 8%, 9%, 10%, ormore than 10% of the composition. In some embodiments, the active agent isprovided at least or about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%,20%, 22%, 24%, 26%, 28%, 30% or more than 30% of the composition. In someembodiments, the active agent is provided in a range of about 0.1% to about 2.5%,about 0.2% to about 1%, about 0.3% to about 0.8%, or about 0.5% by weight of theaqueous phase surrounded by the membrane.An addition ratio of the hydrogel to the active ingredients in the aqueous solutionof the complex of the Mequinol and Curcumin is preferably 0.01% to 50.0%, whichmeans a weight ratio of the hydrogel to the Mequinol and Curcumin. Thiscorresponds to a weight ratio of drug to hydrogel between 1:0.0001 and 1:0.5. Thisratio ensures optimal mixing, stability, and functional performance of the finalformulation.Edge activators function as membrane-destabilizing factors to increase thedeformability of vesicle membranes and, when combined in a proper ratio with anappropriate lipid, gives the optimal mixture, enabling the crypto-transethosomes tobecome deformable, as well as ultra-flexible, which results in a higher permeationcapability. Edge activators are amphiphilic molecules that contain a lipophilic alkylchain that is connected to a hydrophilic head group. The edge activator may beselected from cationic PEG derivatives, surfactants, anionic surfactants, or nonionicsurfactants with an uncharged polar head group. Nonionic surfactants areconsidered less toxic and less hemolytic, as well as less irritating to cellularsurfaces, and they tend to maintain a near physiological pH in a solution. variousnonionic surfactants and emulsifiers such as polysorbates, e.g. polyethylene sorbitolester (polysorbate-type) nonionic surfactants such as polysorbate-20, polysorbate-40, polysorbate-60, and polysorbate-80. Commercially available polysorbatesinclude the "Tweens", condensates of sorbitol fatty acid ester and ethylene oxide,common commercial brand names of which include Scattics, ALKEST TW 20,and TWEEN 20. In some aspects, the edge activator is polysorbate-80, thegeneric name for which is polyoxyethylene (20) sorbitan monooleate, and which iscommercially available as TWEEN 80. Other polysorbates are generallycommercially available under similar naming conventions, e.g.TWEEN 20, TWEEN 40, TWEEN 60, etc. Additional edge activatorsinclude the "Spans", such as SPAN 60, SPAN 65, SPAN 80, etc., sodiumcholate, sodium deoxycholate, and dipotassium glycyrrhizinate. In someembodiments, the edge activator is present in an amount of 5-30% w / w, e.g. 10-25% w / w. More preferable edge activators are Tween 80 and PEG 6000. In someembodiments, the edge activator is present in an amount of 5-30% w / w, e.g. 10-25% w / w.The presence of ethanol in the lipid layer of the crypto-transethosome provides asofter and malleable vesicle structure, which gives more freedom, elasticity andstability to its membrane. In some embodiments, the ethanol is present in ahydration medium, e.g. water or a buffer solution such as a phosphate buffersolution, in an amount of 5-60% v / v. e.g. 12-50% v / v.The cryptotransethosomes may contain may contain one or more additionalcomponents such as a permeation enhancer (e.g. glycols such as propylene glycol,C3-C4 alcohols, etc.).The formulation of Mequinol and Curcumin loaded Crypto-transethosomal gel wasprepared by varying concentrations of lecithin and varying concentration of gellingagent (Carbopol 934) using Ethanol-Injection method. The drug concentrationswere kept constant for each formulation (1% Mequinol and 0.1 % Curcumin).In one embodiment, a surface of the crypto-transethosome is modified with acationic charge inducing agent such as stearylamine, 1-alanine benzyl ester, orcetyltrimethylammonium bromide. The presence of positive charges on the vesiclesurface allows for interaction with the negatively charged cell membrane, whichenhances the penetration and effect. In some embodiments, the stearyl amine ispresent in an amount of 10-20% w / w of the total lipid. The zeta potential value,which indicates surface charge of the particles, generally ranges from +30-40 mV,e.g. about +33-37 mV.The entrapment efficiency (EE) of the crypto-transethosomes generally ranges fromabout 80 to 100%, e.g. is at least about 80, 85, 90, 95 or 100%. In some aspects, theEE ranges from about 90-100%.The flexibility value of the crypto-transethosomes generally ranges from about 90to 100%, e.g. is about 91, 92, 93, 94, 95, 96, 97, 98, or 99%. Flexibility of thenanoparticles refers to the change in the nanoparticle size after extrusion underreduced pressure across a membrane filter of a specific pore size.The crypto-transethosomes described herein are useful for delivery of asubstantially insoluble or sparingly soluble biologically active agent to a human ornon-human animal subject. In some embodiments, the active agent has a solubilityin water (w / v) which is 3% or less, e.g. 1% or less. In some embodiments, the activeagent is ketoconazole. In some embodiments, the ketoconazole is present in anamount of 0.05-0.2% w / v of the total formulation volume.In some embodiments, the crypto-transethosomes described herein are incorporatedinto in situ gelling (ISG) compositions. The ISG preparation may provide anextended drug residence time, accurate dosing, and extended shelf-life.Additional components such as a viscosity modifier, e.g. hydroxypropylmethylcellulose (HPMC), may be added to the ISG composition. In someembodiments, the HPMC is present in an amount of 0.2-0.8% w / v of the totalformulation.Suitable pharmaceutically acceptable carriers include but are not limited to water,salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethyleneglycols, gelate, carbohydrates such as lactose, amylose or starch, magnesiumstearate talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglyceridesand diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose,polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and ifdesired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers,wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring,flavoring and / or aromatic substances and the like. Other suitable excipients include,for example an inert diluent such as lactose; granulating and disintegrating agentssuch as cornstarch; binding agents such as starch; and lubricating agents such asmagnesium stearate.The compositions of the present disclosure may also contain other components suchas, but not limited to, antioxidants, additives, adjuvants, buffers, tonicity agents,bioadhesive polymers, and preservatives. It should be appreciated that thecompositions of the present disclosure may be buffered by any common buffersystem such as phosphate, borate, acetate, citrate, carbonate and borate-polyolcomplexes, with the pH and osmolality adjusted in accordance with well-knowntechniques to proper physiological values.An additive such as a sugar, a glycerol, and other sugar alcohols, can be includedin the compositions of the present disclosure. Non-limiting examples ofpharmaceutical additives of the present disclosure include sugars, such as,trehalose, mannose, D-galactose, and lactose.In an embodiment, if a preservative is desired, the compositions may optionally bepreserved with any well-known system such as benzyl alcohol with / without EDTA,benzalkonium chloride, chlorhexidine, Cosmocil CQ, or Dowicil 200.Embodiments of the disclosure include methods of preparing crypto-transethosomes, in situ gelling compositions, and hydrogel compositions asdescribed herein.The crypto-transethosomes may be prepared according to a thin film hydrationmethod in which the drug, phospholipid, and edge activator are dissolved in asolvent such as methanol. The mixture may be subject to homogenization, e.g. usinga water bath sonicator, to obtain a homogenous dispersion. The solvent is removedunder reduced pressure until a thin clear lipid film is formed. The dried lipid filmmay then be hydrated in a hydration medium such as phosphate buffer containingethanol and propylene glycol. The prepared crypto-transethosomes formulationsmay then be subjected to probe sonication to achieve particle size reduction.Formulations may be prepared by simple dispersion of the gelling agent in a knownvolume of the drug loaded crypto-transethosomes formulation over a magneticstirrer.Various methods are used to prepare Cryptosome including Thin Film Hydration,Ethanol Injection Method, Cold Method, Reverse Phase Evaporation Method andFreeze-Thaw + Sonication Technique (Stability Enhancement). Hydrogels mayalso be prepared by dispersion by adding the polymer to a known volume of thedrug loaded crypto-transethosomes formulation over a magnetic stirrer.Thin film hydration method involves the process of preparing Lipid bilayer(Cryptosome part) and then ethanol and edge activators (Transethosome part) areincorporated. Initial step of dissolving phospholipids (e.g., Phosphatidylcholine),cholesterol, and lipophilic drug (e.g., curcumin) in an organic solvent(chloroform / methanol). Then the solvent is evaporated under reduced pressureusing rotary evaporator to form a thin lipid film. Then the film was hydrated withaqueous phase containing ethanol, hydrophilic drug (e.g., Mequinol), edge activatorand coating agent (Tween 80 & PEG / Poloxamer 188). The resultant product wassubjected to dispersion using probe sonication or extrusion results in nano-sizedcrypto-transethosomes.Another method of Ethanol Injection Method involves the process of rapid injectionof ethanolic lipid phase into aqueous surfactant phase. The first step of dissolvingphospholipids and lipophilic drug in ethanol. The aqueous phase containinghydrophilic drug and edge activators ((Tween 80) was prepared into whichethanolic lipid solution was injected dropwise with continuous stirring at controlledtemperature. In this step, the crypto coating agents were incorporated. The resultantvesicles self-assemble into flexible hybrid bilayers (crypto-transethosomes).Further the Cold Method (for Thermolabile Drugs) involves the process ofdissolving phospholipids, edge activator and cholesterol in ethanol at 30°C. Furtherthe aqueous phase with drug (hydrophilic) and crypto coating agent was preparedand the resultant aqueous phase was added slowly into ethanolic lipid mixture undercontinuous stirring. Further it was sonicated to reduce size stable vesicles.Another method of preparing vesicles is Reverse Phase Evaporation Method usefulwhen high entrapment of both hydrophilic and hydrophobic drugs is required. Themethod involves steps of dissolving lipids in organic solvent (diethylether / isopropyl ether +chloroform). Further it was emulsified with aqueous drugsolution (containing ethanol + surfactant). Further the solvent was removed underreduced pressure and the vesicle formation with internal aqueous core (forhydrophilic drug) and bilayer (for lipophilic drug) followed by coating with cryptocoating agent.Another method of preparing vesicle is Freeze-Thaw + Sonication Technique(Stability Enhancement) involve the principle of improving bilayer integrity andentrapment efficiency. The method includes the step of preparing vesicle dispersion(thin film hydration / ethanol injection) and subjected to dispersion of repeatedfreeze-thaw cycles (liquid nitrogen / freezer water bath). Further it was sonicatedand extruded for uniform size.The present disclosure also provides a method for the delivery of an Mequinol andCurcumin to a human or non-human animal subject in need thereof by ocularlyadministering to said subject a crypto-transethosome composition, in situ gellingcomposition, or hydrogel composition as described herein. Crypto-transethosomeis made up of phospholipids like distearoyl phosphatidylethanolaminepolyethyleneglycol and distearoylphosphatidylcholine (DSPE-PEG).A patient or subject to be treated by any of the compositions or methods of thepresent disclosure can mean either a human or a non-human animal including, butnot limited to dogs, horses, cats, rabbits, gerbils, hamsters, rodents, birds, aquaticmammals, cattle, pigs, camelids, and other zoological animals.Before exemplary embodiments of the present invention are described in greaterdetail, it is to be understood that this invention is not limited to particularembodiments described, as such may, of course, vary. It is also to be understoodthat the terminology used herein is for the purpose of describing particularembodiments only, and is not intended to be limiting, since the scope of the presentinvention will be limited only by the appended claims.The invention is further described by the following non-limiting examples whichfurther illustrate the invention, and are not intended, nor should they be interpretedto, limit the scope of the invention.EXAMPLESMethod of PreparationA) Preparation of Crypto-Transethosomesi. Organic Phase PreparationThe organic phase was prepared by accurately weighing phosphatidyl choline anddissolving it in ethanol. The solution was maintained at 30°C to ensure completesolubilization. Subsequently, Mequinol and Curcumin were added to the organicsolution under continuous stirring until a homogenous mixture was obtained.ii. Aqueous Phase PreparationThe aqueous phase was prepared by dissolving Tween 80 in distilled watermaintained at 30°C. The solution was stirred gently to ensure complete dissolutionand uniformity of the surfactant.iii. Vesicle FormationVesicles were formed by slowly injecting the organic phase into the aqueous phaseunder continuous magnetic stirring. Stirring was maintained for 50 minutes tofacilitate the spontaneous formation of vesicular structures and ensure homogeneityof the dispersion. Ater 10 minutes of stirring, slowly incorporate PEG 6000 into thedispersion.iv. Maturation of VesiclesThe prepared vesicular dispersion was stored at 4°C for 12 hours to allowstabilization and maturation of the vesicles. This step ensures uniform vesicle sizeand enhances encapsulationefficiency.v. Preparation of Gel BaseA suitable gelling agent, such as Carbopol 934 (0.5-2% w / v), was dispersed indistilled water under gentle stirring. The dispersion was allowed to hydrate forseveral hours at room temperature or overnight in the refrigerator to achievecomplete swelling of the polymer. Triethanolamine was then added dropwise withconstant stirring until the pH reached 4.5-6.0, forming a clear, uniform gel suitablefor incorporation of vesicular dispersion.B) Incorporation of Crypto-Transethosomes Suspension into GelThe prepared Crypto-Transethosome dispersion was slowly incorporated into thegel base under gentle stirring to avoid air entrapment. The final vesicular gel wasthen transferred into airtight containers and stored in a cool place until further use.Table 01. Composition of Mequinol and Curcumin Loaded Crypto-Transethosomal GelThe mean vesicle size of the prepared formulations (F1-F9) ranged from 908.3 nm(F7) to 1017.05 nm (F9), indicating formation of nanosized vesicular carrierssuitable for topical delivery. Among all formulations, F6 exhibited an averagevesicle size of 976.4 ± 172.08 nm, which is within the optimal nanometric rangefor efficient skin permeation while maintaining structural integrity. Importantly, F6also displayed the lowest polydispersity index (PDI = 0.0270), signifying a narrowsize distribution and greater uniformity compared to other formulations. A lowerPDI is desirable as it reflects formulation stability and reproducibility, which arecritical for consistent dermal drug delivery.Although F9 also demonstrated a comparable PDI (0.0273), its particle size was thelargest (1017.05 nm), which may limit skin penetration efficiency. In contrast, F6balanced smaller vesicle size with high homogeneity, establishing it as the bestcandidate formulation for further evaluation.The zeta potential of the prepared formulations ranged between -0.2 mV and -0.6mV, suggesting the formation of weakly charged vesicular systems. Among all, F6and F9 displayed the highest negative potential (-0.6 mV), indicating relativelybetter colloidal stability compared to other formulations. These results suggest thesuccessful entrapment of the vesicle within the PEG coating, which provides stericstabilization and thereby prevents vesicle aggregation.The entrapment efficiency percentage of the prepared formulations (F1-F9) rangedfrom 65.986 to 83.843.The viscosity of Crypto-Transethosomal gel was measured by using Brookfieldviscometer. All the formulations depicting viscosity range from 4400 - 6400 cps.The formulation F9 has the highest viscosity about 6348 ± 13.01 cps.The spreadability of a topical formulation is a critical parameter, as it determinesthe ease of application, uniformity of drug distribution, and overall patientacceptability. The spreadability of the developed Crypto-Transethosomal Gel wasevaluated using the glass slide method, and the readings were noted in triplicate andaverage values were calculated and the results were shown in table.A higher spreadability value corresponds to lower resistance during application andgreater ease of spreading, which is desirable for patient compliance. In the presentstudy, the formulation exhibited good spreadability within the acceptable range (8-15 g-cm / sec), confirming that the gel can be easily applied to the skin with minimaleffort and without stickiness.Table 2. Viscosity, pH and Spreadability of Crypto-Transethosomal GelThe in-vitro drug release study using the Franz diffusion cell showed that Mequinolpermeated significantly faster than Curcumin from the developed CTE gel. At 6 h,the cumulative amount of Mequinol permeated was around 9.22 mg / cm2 comparedto ~0.93 mg / cm2 for Curcumin. This difference can be explained by thephysicochemical properties of the two drugs: Mequinol, being smaller and morehydrophilic, diffuses more readily into the receptor medium, while Curcumin ishighly lipophilic and remains more associated with the vesicular matrix, leading toslower and sustained release.The calculated steady-state flux was much higher for Mequinol (~1109 μg / cm2 / h)than for Curcumin (~116 μg / cm2 / h). Importantly, the vesicle size (~1000 nm)restricts systemic exposure, ensuring that drug activity is largely confined to theskin layers. In this system, Mequinol serves as the primary melanocytotoxic agent,while Curcumin mainly contributes to Glutathione S-transferase (GST) inhibition,enhancing local therapeutic effectiveness. The additional anticancer activity ofCurcumin can be considered a supportive benefit rather than the main functionaloutcome.Overall, these results indicate that the CTE gel provides a dual advantage: rapid andeffective dermal delivery of Mequinol along with a sustained, enzyme-modulatingeffect of Curcumin, which together may improve local treatment efficacy whileminimizing systemic side effects.Cytotoxicity Analysis (MTT Assay) - Method for Test Formulation in MelanomaCell LinesThe cytotoxic effect of the test formulation on melanoma cells was evaluated usingthe MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]colorimetric assay. After performing the MTT assay, the percentage of cell viabilityfor each concentration of formulation (6.25, 12.5, 25, 50, & 100 μg / mL) wascalculated relative to the untreated control, which was set as 100% viability.Table 03. Mean Percentage Cytotoxicity with Standard Deviation (SD) and StandardError of Mean (SEM)The crypto-transethosomal gel reduced A375 cell viability in a dose-dependentmanner. At 6.25 μg / mL, viability remained high (~95%), while at 12.5 μg / mL,viability dropped to ~87%. A significant decline was seen at 25 μg / mL (~72%) and50 μg / mL (~55%). At the highest tested concentration (100 μg / mL), viability fellto ~22%, indicating ~78% inhibition compared to untreated control.The plotted curve showed a sigmoidal dose-response pattern, consistent withtypical cytotoxic drug behaviour. Nonlinear regression analysis (GraphPad Prism)yielded an IC50 of ~35-40 μg / mL, indicating the concentration required to reducecell viability by 50%.Cytotoxicity studies on A375 melanoma cells confirmed potent dose-dependentcytotoxic activity, with an IC50 of 43.49 μM, supporting the therapeutic potential ofthe formulation. In vivo dermal irritation studies showed no visible signs oferythema or edema up to 72 hours, as monitored at 24-hour intervals, confirmingthe excellent biocompatibility and skin safety of the developed formulations. whilerapid dermal absorption was observed within 10 minutes post-application.Mequinol (4-hydroxyanisole) acts as a melanocytotoxic agent, selectivelydamaging melanocytes and melanin-producing tumor cells through oxidative stressand cytotoxic byproducts. Curcumin complements by inhibiting NF-κB / MAPKsignaling, inducing apoptosis, and suppressing tumor proliferation. The crypto-transethosomal carrier enhances solubility, stability, and intracellular uptake,resulting in synergistic cytotoxicity.The obtained IC50 value is within the pharmacologically relevant range formelanoma treatment reported in literature. Results are consistent with previousstudies on Curcumin and Mequinol as anticancer agents, but the vesicularencapsulation improved potency and delivery.The crypto-transethosomal gel shows significant dose-dependent cytotoxicityagainst A375 melanoma cells. Findings confirm the formulation's therapeuticpotential as a topical melanoma treatment, warranting further ex-vivo andpreclinical validation.In Vivo Dermal Irritation StudyThe dermal irritation study was conducted to evaluate the safety and tolerability ofthe developed formulation upon topical application. Dermal irritation studies aredesigned to assess adverse cutaneous reactions such as erythema (redness), edema(swelling), or other inflammatory responses following topical application of theformulation. The formulation was applied to Albino rats and monitored for 72 hourspost-application. The results were noted.Table 04 Draize ScoringScoring based on Draize scale (0 = no reaction, 1 = very slight, 2 = well-defined, 3 = moderate tosevere, 4 = severe reaction).In vivo dermal irritation and skin absorption studies in albino rats showed no signsof erythema or edema up to 72 hours, and complete absorption occurred within 10minutes of application. These findings confirm excellent skin compatibility andrapid permeation of the formulation, ensuring selective action against melanocyteswithout affecting normal cells such as keratinocytes.In vivo dermal irritation and skin absorption studies in albino rats showed no signsof erythema or edema up to 72 hours, and complete absorption occurred within 10minutes of application. These findings confirm excellent skin compatibility andrapid permeation of the formulation, ensuring selective action against melanocyteswithout affecting normal cells such as keratinocytes.Collectively, these findings establish that the Mequinol-Curcumin Crypto-Transethosomal gel offers a targeted, sustained, and synergistic therapeuticapproach for topical Melanoma treatment.The formulation provides enhanced drug penetration, prolonged skin retention, andsustained release while minimizing systemic exposure and irritation risks. Thiswork demonstrates that the developed gel can potentially improve the efficacy andsafety of topical Melanoma therapy.

Claims

1. A topical gel composition for melanoma treatment comprising: a) one or more anticancer agent; and b) crypto-transethosome comprising ethanol, phosphatidyl choline, Tween 80 and PEG 6000 wherein the anticancer agent is encapsulated within the cryptotransethosome.

2. The topical gel composition as claimed in claim 1, wherein the anticancer agent is selected from the group consisting of Mequinol and Curcumin.

3. The topical gel composition as claimed in claim 1, wherein the gelling agent is selected from the group consisting of Carbopol 934, sodium alginate, poloxamer 407, and prop-2-enoic acid.